Complete Story
04/20/2020
Merck's Biosimilar ONTRUZANT® (trastuzumab-dttb) is Available through Specialty Distributors and Wholesalers
Merck Sharp & Dohme Corp. (“Merck”), a subsidiary of Merck & Co., Inc., is pleased to announce that ONTRUZANT® (trastuzumab-dttb) for injection, for intravenous use 21 mg/mL, a biosimilar* to Herceptin® (trastuzumab), is available through specialty distributors and wholesalers. Please contact your specialty distributor or wholesaler to confirm product availability.
*Biosimilar means that the biological product is approved based on data demonstrating that it is highly similar to an FDA-approved biological product, known as a reference product, and that there are no clinically meaningful differences between the biosimilar product and the reference product. Biosimilarity of ONTRUZANT has been demonstrated for the condition(s) of use (eg, indication(s), dosing regimen(s), strength(s), dosage form(s), and route(s) of administration described in its Full Prescribing Information).
ONTRUZANT is available as follows:
PRODUCT |
HCPCS CODE1 |
DESCRIPTOR1 |
HOW SUPPLIED |
NDC |
CATALOG PRICEa |
ONTRUZANT | Q5112 |
Injection, trastuzumab-dttb, biosimilar (ONTRUZANT), 10 mg |
Carton with one 150-mg vial, single-dose Carton with one 420-mg vial, multi-dose |
0006-5033-02 0006-5034-02 |
$1,324.66 $3,709.04 |
Indications and Usage: CLICK HERE
Selected Safety Information: CLICK HERE
Report Broken Links
Have you encountered a problem with a URL (link) on this page not working or displaying an error message? Help us fix it!